1. Home
  2. CHRS vs NIM Comparison

CHRS vs NIM Comparison

Compare CHRS & NIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • NIM
  • Stock Information
  • Founded
  • CHRS 2010
  • NIM 1992
  • Country
  • CHRS United States
  • NIM United States
  • Employees
  • CHRS N/A
  • NIM N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • NIM Trusts Except Educational Religious and Charitable
  • Sector
  • CHRS Health Care
  • NIM Finance
  • Exchange
  • CHRS Nasdaq
  • NIM Nasdaq
  • Market Cap
  • CHRS 112.5M
  • NIM 112.6M
  • IPO Year
  • CHRS 2014
  • NIM N/A
  • Fundamental
  • Price
  • CHRS $0.78
  • NIM $9.02
  • Analyst Decision
  • CHRS Buy
  • NIM
  • Analyst Count
  • CHRS 3
  • NIM 0
  • Target Price
  • CHRS $4.68
  • NIM N/A
  • AVG Volume (30 Days)
  • CHRS 1.5M
  • NIM 35.4K
  • Earning Date
  • CHRS 05-12-2025
  • NIM 01-01-0001
  • Dividend Yield
  • CHRS N/A
  • NIM 3.46%
  • EPS Growth
  • CHRS N/A
  • NIM N/A
  • EPS
  • CHRS N/A
  • NIM N/A
  • Revenue
  • CHRS $272,251,000.00
  • NIM N/A
  • Revenue This Year
  • CHRS N/A
  • NIM N/A
  • Revenue Next Year
  • CHRS $19.78
  • NIM N/A
  • P/E Ratio
  • CHRS $1.83
  • NIM N/A
  • Revenue Growth
  • CHRS 19.87
  • NIM N/A
  • 52 Week Low
  • CHRS $0.66
  • NIM $8.28
  • 52 Week High
  • CHRS $2.43
  • NIM $9.74
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 40.90
  • NIM 46.05
  • Support Level
  • CHRS $0.74
  • NIM $8.80
  • Resistance Level
  • CHRS $0.82
  • NIM $9.12
  • Average True Range (ATR)
  • CHRS 0.07
  • NIM 0.11
  • MACD
  • CHRS -0.00
  • NIM -0.01
  • Stochastic Oscillator
  • CHRS 19.71
  • NIM 55.00

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About NIM Nuveen Select Maturities Municipal Fund

Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital by investing in an investment-grade quality portfolio of municipal obligations with intermediate characteristics.

Share on Social Networks: